Eric Reeves, MD
Interventional Cardiology · Shreveport, LANPI 1710060280
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Edwards Lifesciences at 41.8% of the total. Reporting peaked in 2022 at $9,137 and has fallen 70.9% since, to $2,659 in 2025.
Across 295 payments — averaging $90.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$11K
- Medtronic$10K
- Abbott$3K
- Abiomed$682
- Boston Scientific$562
- Inari Medical, Inc.$514
- plus $2K from 23 others
What the payments were for
- Consulting fees$3,25012%
- Speaking & faculty fees$10,43839%
- Travel & lodging$4,33116%
- Food & beverage$8,70332%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 60 | $11,198 |
| Medtronic(2 entities) | 56 | $9,522 |
| Abbott | 29 | $2,587 |
| Abiomed | 20 | $682 |
| Boston Scientific | 20 | $562 |
| Inari Medical, Inc. | 21 | $514 |
| Stryker | 15 | $268 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $153 |
| Pfizer | 9 | $143 |
| Shockwave Medical, Inc | 4 | $143 |
| Kestra Medical Technology Services, Inc. | 4 | $142 |
| Heartflow, Inc. | 2 | $130 |
| E.r. Squibb & Sons, L.L.C. | 7 | $117 |
| Sanofi-aventis U.S. LLC | 7 | $107 |
| Astellas Pharma US Inc | 1 | $99 |
| Philips North America LLC | 4 | $93 |
| Amgen | 5 | $73 |
| Johnson & Johnson | 3 | $47 |
| Inspire Medical Systems, Inc. | 1 | $47 |
| Novo Nordisk | 2 | $38 |
| Silk Road Medical, Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
| Novartis | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Elutia, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$7,712
- Edwards SAPIEN 3 Transcatheter Heart Valve$6,852
- PASCAL$1,761
- NAVITOR$960
- Impella$264
- SAPIEN 3 Ultra RESILIA$218
- MitraClip System$125
- CoreValve Evolut$124
- GENERAL - STRUCTURAL HEART$122
- FFRct$110
How this compares
$26,820 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 368 | $285,607 |
| EntrestoSacubitril/Valsartan | 194 | $165,466 |
| XareltoRivaroxaban | 75 | $63,014 |
| MultaqDronedarone Hcl | 43 | $48,372 |
| Repatha SureclickEvolocumab | 11 | $9,080 |
| Ranolazine ErRanolazine | 85 | $5,850 |
| Metoprolol Succinate | 425 | $4,050 |
| ClopidogrelClopidogrel Bisulfate | 404 | $3,720 |
| Atorvastatin Calcium | 341 | $3,261 |
| Valsartan | 105 | $2,898 |
| Metoprolol Tartrate | 420 | $2,113 |
| Potassium Chloride | 180 | $2,067 |
| Carvedilol | 246 | $1,748 |
| Flecainide Acetate | 41 | $1,686 |
| Rosuvastatin Calcium | 87 | $1,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $285,607368 claims |
| NovartisEntresto | $17 | $165,466194 claims |
| Johnson & JohnsonXarelto | $47 | $63,01475 claims |
| Sanofi-aventis U.S. LLCMultaq | $107 | $48,37243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Shreveport
- Steven BaileyShreveport$305K
- Tarek HelmyShreveport$46K
- James SmithShreveport$31K
- Boshra LoukaShreveport$23K
- Pavan KatikaneniShreveport$20K
- George MinaShreveport$19K
- Paul DavisShreveport$16K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.